Skip to main content
main-content

Prostate cancer

Prostate cancer

14-02-2020 | Oncology | News | Article

CARD: Favorable metastatic CRPC PROs observed with cabazitaxel

The patient-reported outcomes from the CARD trial of third-line cabazitaxel in men with metastatic castration-resistant prostate cancer add support for using the taxane in this setting, say researchers.

14-02-2020 | Oncology | News | Article

Long-term CHHiP data further support hypofractionated radiotherapy for prostate cancer

The 8-year results from the phase 3 CHHiP trial have confirmed the noninferiority of moderately hypofractionated radiotherapy delivering 60 Gy in 20 fractions to the conventional regimen for the control of localized prostate cancer.

14-02-2020 | Oncology | News | Article

​​​​​​​STOMP 5-year results confirm potential of metastasis-directed therapy in prostate cancer

Metastasis-directed therapy for oligometastatic recurrent prostate cancer continues to be associated with better androgen deprivation therapy-free survival relative to surveillance at 5 years, show follow-up findings from the STOMP trial.

11-02-2020 | Oncology | News | Article

Incorporating genetic risk may help personalize prostate cancer screening strategies

Combining a single nucleotide polymorphism-based genetic risk score for prostate cancer with family history could improve the stratification of inherited risk and help personalize screening strategies, research suggests.

04-02-2020 | Oncology | Highlight | News

Darolutamide receives positive EMA decision for nonmetastatic CRPC

Click through for more information

03-02-2020 | Oncology | News | Article

PROs support use of hypofractionated radiation in nonmetastatic prostate cancer

Real-world data show comparable patient reported functional outcomes and health-related quality of life between nonmetastatic prostate cancer patients who were treated with moderately hypofractionated or conventionally fractionated radiation therapy.

24-01-2020 | Oncology | News | Article

Healthy older men may benefit from prostate cancer screening

The risk for clinically significant prostate cancer rises with age, report researchers who believe that this should be taken into account in the optimization of screening practices.

24-01-2020 | Oncology | News | Article

​​​​​​​ASCO issues prostate cancer imaging, biomarker test guidelines

Read more on these recommendations here

23-01-2020 | Oncology | News | Article

Eating more vegetables does not reduce low-grade prostate cancer progression risk

A behavioral intervention to increase vegetable consumption does not reduce the risk for disease progression over 2 years in men with early-stage prostate cancer undergoing active surveillance, phase 3 study data show.

17-01-2020 | Oncology | News | Article

Similar outcomes with neoadjuvant and concurrent sequencing of ADT, prostate RT

Biochemical relapse-free survival and overall survival rates are comparable in men with localized prostate cancer who start androgen-deprivation therapy before or at the same time as dose-escalated prostate radiotherapy, phase 3 study data show.

16-01-2020 | Oncology | News | Article

PSA repeat screening strategy should be tailored to baseline PSA

Baseline prostate-specific antigen levels in men screened between the ages of 55 and 60 years are significantly associated with long-term risk for clinically significant prostate cancer, shows an analysis of data from the PLCO Cancer Screening Trial.

15-01-2020 | Oncology | News | Article

Prostatectomy-associated urinary incontinence disparities persist at 5 years

Men with favorable- and unfavorable-risk prostate cancer who undergo prostatectomy report worse urinary incontinence at 5 years than men treated with other contemporary management options, US research shows.

03-01-2020 | Prostate cancer | News | Article

Pembrolizumab may be an option for treatment-refractory mCRPC

Pembrolizumab monotherapy shows activity against both RECIST-measurable and bone-predominant treatment-refractory metastatic castration-resistant prostate cancer, results of the KEYNOTE-199 phase 2 trial show.

20-12-2019 | Oncology | News | Article

Enzalutamide, enfortumab vedotin-ejfv receive FDA nods

Click here for more information

19-12-2019 | Oncology | News | Article

‘Reverse migration’ of prostate cancer in USA following 2012 USPSTF recommendations

Prostate cancer has undergone “reverse migration” away from indolent disease and toward more aggressive presentation in the USA following recommendations against prostate-specific antigen screening, say researchers.

12-12-2019 | Oncology | News | Article

Ambulation outcomes not quite noninferior with single vs multifraction radiotherapy

Researchers have been unable to show that single-dose radiotherapy is not inferior to multifraction radiotherapy in terms of ambulatory status in patients with metastatic prostate, lung, or breast cancer and spinal cord or cauda equina compression.

10-12-2019 | Oncology | News | Article

Anti-STEAP1 antibody shows acceptable safety profile in mCRPC

DSTP3086S, a humanized immunoglobulin G1 monoclonal antibody that targets six-transmembrane epithelial antigen of the prostate 1 has shown promising results in a phase 1 study of metastatic castration-resistant prostate cancer.

09-12-2019 | Oncology | Highlight | Article

Nivolumab shows promise in ‘wide variety’ of mismatch repair-deficient cancers

Nivolumab elicits promising response rates in noncolorectal treatment-refractory cancers with mismatch repair deficiency, suggest phase 2 study results.

25-11-2019 | Oncology | News | Article

Real-world cabazitaxel survival outcomes fall below clinical trial data

Overall survival rates among men receiving cabazitaxel for metastatic castration-resistant prostate cancer are lower in everyday oncology practice than previously observed in clinical trials, French study data show.

19-11-2019 | Oncology | News | Article

Abiraterone best given before, not after, enzalutamide in mCRPC

A sequencing strategy that uses abiraterone acetate plus prednisone followed by enzalutamide, rather than the opposite, provides the greatest clinical benefit to patients with newly diagnosed metastatic castration-resistant prostate cancer, researchers report.

Image Credits